Will the vaccine supply problem be solved?… British government expectations
There is also an expectation that cross-vaccination may exert a greater effect on the mutant virus.
According to the UK Daily Guardian, researchers at Oxford University will administer one of the two types of vaccine to the experimenter, and then test the immune response by vaccinating the previous vaccine and another type of vaccine every 4 to 12 weeks.
The first is AstraZeneca, the second is the Pfizer vaccine, or the first is the Pfizer and the second is the AstraZeneca vaccine. The test subjects were 820 high-risk volunteers in their 50s or older who have not yet been vaccinated. The UK Vaccine Task Force (TF) team that supported the study said, “A very important study has begun.” “As the continuity of the vaccine supply is problematic, the results of this study will be useful not only in the UK but also around the world.” Said.
The UK Public Health Service (PHE) told the National Health Service (NHS), which is already in charge of vaccination, “If a subject who has completed the first vaccination cannot obtain the vaccine that was originally given at the second vaccination, give a vaccine from another manufacturer.” He has given instructions.
The US Centers for Disease Control and Prevention (CDC) also recommends cross-vaccination only in unavoidable cases, such as relocating to another area after completing the first vaccination at a nursing hospital.
The Oxford team explained that they would see if cross-vaccination would reduce or improve the effectiveness of one type of vaccine compared to two shots.
The Guardian reported that the research team did not rule out the possibility that vaccinating vaccines from different pharmaceutical companies would be effective against mutant viruses originating in the UK, South Africa, and Brazil.
“If we prove we can cross-use these vaccines, this could greatly increase the flexibility of vaccine distribution,” said Matthew Snap, a professor at Oxford University School of Medicine, who leads the team. It could also provide clues on how to increase your protection against the new mutant virus.”
He explained that both AstraZeneca and Pfizer/Bioentech vaccines were developed using messenger ribonucleic acid (mRNA), and that they had confirmed sufficient effectiveness in cross-immunization between the two manufacturers in a previous mouse experiment.
Snap said that if the experiment is successfully completed, it will start cross-inoculation tests of NovaVax and Janssen vaccines developed using Spike protein.
[서울=뉴시스]
Copyright by dongA.com All rights reserved.
—
–
